
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) **July 10, 2007 (July 5, 2007)**



CHEMBIO DIAGNOSTIC, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction
of Incorporation)

0-30379

(Commission File Number)

88-0425691

(IRS Employer
Identification Number)

3661 Horseblock Road

Medford, NY 11763

(Address of principal executive offices)

631-924-1135

(Registrant's Telephone Number)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 7.01. Regulation FD Disclosure.

On July 5, 2007, the Company issued a press release titled “Chembio to Present at 2007 C.E. Unterberg Towbin Emerging Growth Opportunities Conference.” The press release is attached hereto as Exhibit 99.1.

On July 10, 2007, the Company issued a press release titled “CORRECTING AND REPLACING Chembio to Present at 2007 C.E. Unterberg Towbin Emerging Growth Opportunities Conference.” The press release is attached hereto as Exhibit 99.2.

On July 11, 2007, certain officers of the Company intend to deliver an investor presentation that will include the slides attached hereto as Exhibit 99.3 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached as Exhibit 99.3.

ITEM 9.01. Financial Statements and Exhibits

(d) Exhibits.

99.1 Press Release titled “[Chembio to Present at 2007 C.E. Unterberg Towbin Emerging Growth Opportunities Conference](#)” issued July 5, 2007.

99.2 Press Release titled “[CORRECTING AND REPLACING Chembio to Present at 2007 C.E. Unterberg Towbin Emerging Growth Opportunities Conference](#)” issued July 10, 2007.

99.3 PDF of [Chembio Presentation](#) to be delivered on July 11, 2007.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing. This Current Report on Form 8-K does not constitute a determination of whether any information included herein is material.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: July 10, 2007

Chembio Diagnostics, Inc.

By: /s/ Lawrence A. Siebert
Lawrence A. Siebert
Chief Executive Officer



ChemBio to Present at 2007 C.E. Unterberg Towbin Emerging Growth Opportunities Conference

MEDFORD, N.Y. - July 5, 2007 - ChemBio Diagnostics Inc.'s (OTCBB: CEMI) Chief Executive Officer, Lawrence Siebert, will present at the 2007 C.E. Unterberg Towbin Emerging Growth Opportunities Conference on Thursday, July 12th at 3:00PM (EDT) at New York City's Mandarin Oriental Hotel. A live webcast of the presentation will be available on the Company's website at www.chembio.com. Additional information regarding the conference can be found at www.unterberg.com.

Mr. Siebert will speak about the market opportunities for the Company's HIV and other rapid diagnostic tests including the FDA approved products being marketed by Inverness Medical Innovations, Inc. as well as ChemBio's newly patented Dual Path Platform (DPP™), for which the Company is generating a significant amount of interest.

ABOUT CHEMBIO

ChemBio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK® HIV 1/2 and HIV 1/2 STAT-PAK® rapid tests, marketed in the United States by Inverness Medical Innovations. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease. In March 2007 ChemBio was issued a United States patent for the Dual Path Platform (DPP(TM)), a next generation lateral flow platform. DPP has demonstrated significant advantages over currently available lateral flow methods, including increased sensitivity, sample flexibility, and multiplexing capabilities.

For further information please visit www.chembio.com.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, ChemBio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for ChemBio's products. ChemBio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in ChemBio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact ChemBio's success are more fully disclosed in ChemBio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact:

Matty Arce - 631-924-1135 ext 123.



CORRECTING AND REPLACING Chembio to Present at 2007 C.E. Unterberg Towbin Emerging Growth Opportunities Conference

MEDFORD, NY – July 10, 2007 - First paragraph, first sentence, the presentation date and time should read Wednesday, July 11th at 2:30pm (EDT) sted: (Thursday, July 12th at 3:00PM (EDT)).

The corrected release reads:

Chembio to Present at 2007 C.E. Unterberg Towbin Emerging Growth Opportunities Conference

Chembio Diagnostics Inc.'s (OTCBB: CEMI) Chief Executive Officer, Lawrence Siebert, will present at the 2007 C.E. Unterberg Towbin Emerging Growth Opportunities Conference on Wednesday, July 11th at 2:30pm (EDT) at New York City's Mandarin Oriental Hotel. A live webcast of the presentation will be available on the Company's website at www.chembio.com. Additional information regarding the conference can be found at www.unterberg.com.

Mr. Siebert will speak about the market opportunities for the Company's HIV and other rapid diagnostic tests including the FDA approved products being marketed by Inverness Medical Innovations, Inc. as well as ChemBio's newly patented Dual Path Platform (DPP™), for which the Company is generating a significant amount of interest.

ABOUT CHEMBIO

Chembio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK® HIV 1/2 and HIV 1/2 STAT-PAK® rapid tests, marketed in the United States by Inverness Medical Innovations. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease. In March 2007 ChemBio was issued a United States patent for the Dual Path Platform (DPP(TM)), a next generation lateral flow platform. DPP has demonstrated significant advantages over currently available lateral flow methods, including increased sensitivity, sample flexibility, and multiplexing capabilities.

For further information please visit www.chembio.com.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, ChemBio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for ChemBio's products. ChemBio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in ChemBio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact ChemBio's success are more fully disclosed in ChemBio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact:

Matty Arce - 631-924-1135 ext 123.
